The Food and Drug Administration (FDA) has approved Eli Lilly’s Foundayo (orforglipron), a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, which offers a noninjectable option for weight management.
Clinical data suggests the drug supports meaningful weight loss and can be taken without strict food or timing requirements, potentially improving ease of use and adherence.
The approval was expedited through the FDA’s National Priority Voucher program, a new initiative designed to speed up access to treatments addressing major public health needs.
Orforglipron’s approval highlights both the growing role of GLP-1 therapies in weight loss and the potential for faster regulatory pathways, bringing new treatments to patients sooner.
